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Brief Report
GTP-Binding Proteins As Oncogenes in
Human Tumors
by Frank McCormick*
Ras oncogenes are the most commonly known onco-
genes in human tumors; their prevalence in different
types of tumors and their role in the development of
these tumors have been discussed in recent reviews
(1,2). We have investigated the biochemical mechanism
that accounts for the activation ofras proto-oncogenes
tobecome oncogenes. Innormalcells, therasp21 cycles
between the active guanosine triphosphate (GTP)-
bound form and the inactive form, bound to guanosine
diphosphate (GDP). The conversion ofthe GTP- to the
GDP-bound form is catalyzed by a cellular protein re-
ferred to as GAP (GTPase activating protein) (3). The
mechanism by which the GTP-bound state is generated
is not known; however, this mechanism must be much
slower than the GAP-catalyzed reaction, so that most
ofthe rasp21 innormal cellsisinthe GDP-bound state.
Inras-transformed cells, the oncogenic mutant ras pro-
tein exists in its GTP-bound state constitutively. This
is because GAP fails to catalyze hydrolysis of GTP
bound to these proteins. Oncogenic mutants can there-
fore be thought of as mutants that escape from this
aspect ofGAP function.
Two types ofGAP cDNA have been cloned from hu-
man placenta (4). Figure 1 shows the structure of the
proteins encoded by these cDNAs. Type I GAP is a
116,000Daprotein, withahydrophobicaminoterminus,
two SH2 regions (src-homology region 2), one SH3 re-
gion, and a catalytic domain comprising the C-terminal
one-third of the protein (5). All cells express type I
GAP, whereas type II, which lacks the first 180 amino
acids oftype I GAP and is generated by an alternative
splicing mechanism, has only been detected in human
placenta and in certain human cell lines, such as MRC-
5 diploid fibroblasts.
Interaction of GAP with ras p21 may have conse-
quences additional to conversion of the GTP-bound to
the GDP-bound form. Thispossibility wasraisedbythe
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discovery that GAP binds to a region of p21 that is
necessary for ras function (6,7), suggesting that GAP
itself might be part of a ras effector system. This hy-
pothesishasnotyetbeenproved, butadditionalsupport
has been provided by the observation that oncogenic
mutants ofras p21 retain their ability to bind GAP (8),
eventhough bindingdoes notlead toGTPase activation
(i.e., downregulation). To date, no ras p21 mutant has
beendescribedthatisbiologicallyactiveyetfailstobind
GAP.
Heterotrimeric G-proteins involved in signal trans-
ductionfromhormonereceptorstointernalsecondmes-
sengers cycle between GTP- and GDP-bound forms in
a similar manner to ras p21 proteins. Again, the active
form is the GTP-bound state. However, these proteins
rely on intrinsic GTPase activity to convert active to
inactive forns, rather than depending on an accessory
proteinsuchasGAP. Althoughthemechanismofdown-
regulation is therefore different, theseproteinsare also
susceptibletoconstitutiveactivationbypointmutations
that lock them in the GTP-bound state. Landis and co-
workers described point mutations in the G-protein al-
pha subunit (the GTP-binding subunit) in human pitui-
tary tumors (9). These mutations occurred at argiline-
201 or glutamine-227. Arginine-201 has no exact hom-
olog in the ras p21 protein, although it is in a region of
Gs-alpha that is equivalent to the GAP-binding region.
Glutamine-227 is the equivalent ofglutamine-61 in ras
p21 (afrequent siteofoncogenicactivation). Bothtypes
ofmutation reduce intrinsic GTPase ofGs-alpha, as ex-
pected for activating mutations.
To extend these observations, we have used poly-
merase chain reaction (PCR) to amplify genomic DNA
from over 300 tumor samples and have analyzed the
frequency of mutations in Gs-alpha in codons 201 and
227 (10). Mutations at these positions occurred in pi-
tuitaryadenomas (43%ofsamplestested)andinthyroid
tumors (4%). We have also initiated a survey of other
G-protein alpha subunits that may be activated in hu-18 F. McCORMICK
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FIGURE 1. Structure ofproteins encoded by GAP cDNAs.
mancancers. Initially, weidentifiedcodonsofGi-2alpha
subunit that are equivalentto codons201 and 227ofGs-
alpha. We then reanalyzed the panel of300 tumor sam-
ples for point mutations at one ofthese positions. Ofall
the tumors tested, tumors ofthe adrenal cortex (27%),
ovarian granulosa (33%), and medullary thyroid (9%)
were found to contain Gi-2 mutations, in all cases at
codon 179, the Gi-2 equivalent of201 in Gs-alpha. The
substitutions produced by these mutations (arginine to
histidineorcysteine) werethesameasthoseofGs-alpha
codon 201, suggesting a common mechanism of activa-
tion.
For Gs-alpha, a major effector is known: this G-pro-
teinturnsonadenylylcyclaseactivity. Effectorsystems
for Gi-2 are less clearly defined. Gi proteins were orig-
inally defined as G-proteins that inhibit adenylyl cy-
clase, butare nowknowntohave otherfunctions, which
may be direct orindirect consequences ofGi activation.
In conclusion, strildng parallels can be drawn be-
tween activation ofras genes in human tumors and ac-
tivationofG-proteins. BothinvolveinhibitionofGTPase
activity, albeit by rather different mechanisms. As a
result, the GTP-binding protein is locked in the GTP-
stateandsignalsconstitutively. However, G-proteinac-
tivation is so far confined to tumors of endocrine func-
tion, whereas ras mutations occur in most types of tu-
mors. Wepresumethatthismeansthatrasp21 proteins
activate pathways that are more intimately involved
with cellular proliferation, whereas those ofG-proteins
aremorespecialized. Inonecase(Gs-alpha)thepathway
isknown, sothatforthefirsttime, anoncogenefunction
can be understood in terms of the second messenger
pathway it controls. We hope that pathways activated
by ras proteins and Giproteins will be elucidated inthe
near future.
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